What Histrelin is
Histrelin is a GnRH agonist peptide analog used in approved endocrine contexts including long-acting suppression strategies.
Histrelin is grouped under Approved / Clinical / Endogenous / Biology on PeptideFactCheck because it helps map the breadth of real peptide endocrine therapeutics.
The useful starting point is to separate the molecule itself from the internet story around it. It helps map the breadth of real peptide endocrine therapeutics.
Why people keep looking it up
It helps map the breadth of real peptide endocrine therapeutics.
Histrelin is a GnRH agonist peptide analog used in approved endocrine contexts including long-acting suppression strategies.
Histrelin tends to stay in the conversation because it touches a familiar public theme: gnrh agonist, hormone suppression, and endocrine medicine. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved endocrine peptide analog with direct human evidence.
Human trials and approved labeling support specific uses.
Mechanistic support follows GnRH receptor pharmacology.
Why this page carries the current tier: Approved endocrine peptide analog with direct human evidence.
The current seed trail for Histrelin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
This is a highly consequential endocrine medication class.
FDA-approved histrelin products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Histrelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Histrelin is CID 25077993. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 25077993
- Formula
- C66H86N18O12
- Molecular weight
- 1323.5
- InChIKey
- HHXHVIJIIXKSOE-QILQGKCVSA-N
Matched synonyms include histrelin, 76712-82-8, Histrelina, Histreline, Histrelinum, ORF 17070, RWJ 17070, ORF-17070.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Histrelin returns 15 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Histrelin returns 150 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- SUPPRELIN LA
- Generic names
- HISTRELIN ACETATE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA022058
Indications and usage. 1 INDICATIONS AND USAGE SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult hei...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Initial Agnostic Action: Initial transient increases of estradiol and/or testosterone may cause a temporary worsening of symptoms ( 5.1 ). Implant Breakage: Have been observed during implant removal. Monitor luteinizing hormone, follicle stimulating hormone or testosterone for suppression of CPP ( 5.2 , 5.6 ) Psychiatric Events: Have been reported in patients taking GnRH agonists. Events i...
Contraindications. 4 CONTRAINDICATIONS SUPPRELIN LA is contraindicated in: Patients who are hypersensitive to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs Pregnancy [see Use in Specific Populations ( 8.1 )] . History of hypersensitivity to gonadotropin releasing hormone (GnRH) or GnRH analogs ( 4 ). Pregnancy ( 4 ).
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.